Business
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent Type C meeting indicated a randomized controlled registrational trial will be required for PBFT02 in FTD-GRN The Company initiated a strategic review process intended to maximize shareholder value PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage gen
About this update from Passage Bio, Inc.
[{"type":"image","alt":"Passage Bio","displaySize":"","headline":null,"caption":"Passage Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":86,"url":"https://media.zenfs.com/en/globenewswire.com/b3c0c02f5e492ae038a6a6abc1f66d66"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nOyIm4lmCgitgZNz3H2m.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMA--/https://media.zenfs.com/en/globenewswire.com/b3c0c02f5e492ae038a6a6abc1f66d66","width":300,"height":86}},"lazy":false},{"type":"text","content":"PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels ","length":174,"tagName":"p"},{"type":"text","content":"FDA feedback from recent Type C meeting indicated a randomized controlled registrational trial will be required for PBFT02 in FTD-GRN ","length":133,"tagName":"p"},{"type":"text","content":"The Company initiated a strategic review process intended to maximize shareholder value ","length":87,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations. In addition, the Company shared feedback from a recent Type C meeting with the United States Food and Drug Administration (FDA) on the likely registrational pathway for PBFT02 in FTD-GRN. The Company has also announced it has engaged Wedbush PacGrow as a financial advisor and has initiated a review of strategic alternatives to maximize shareholder value.","length":737,"tagName":"p"},{"type":"text","content":"Will Chou, M.D., president and chief executive officer of Passage Bio commented, “the data shared today suggest that PBFT02 may slow neurodegeneration in patients with FTD-GRN, with improvements observed in both brain atrophy and plasma neurofilament levels, two well-established biomarkers of disease progression. Further, we continue to observe durable and robust elevations in progranulin, the target protein, and are encouraged by the emerging data from Dose 2 patients, which indicate that this lowe...